SEC Form 4 · accession 0001104659-19-006897
STEMLINE THERAPEUTICS INC · STML
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ivan Bergstein
Officer — Chief Executive Officer · Director
Period of report
Feb 6, 2019
Accepted (ET)
Feb 8, 2019 · 8:52 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001264587
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Feb 6, 2019 | A | 284,748 | $0.00 | A | 2,766,179 | D | |
| Common StockF3,F4 | Feb 6, 2019 | A | 17,009 | $0.00 | A | 2,783,188 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The 284,748 restricted shares will vest in three installments as follows: 94,916 shares on April 14, 2020; 94,916 shares on March 30, 2021; and 94,916 shares on January 18, 2022.
- F2Of the 2,766,179 shares, 1,054,775 shares are restricted stock.
- F3The 17,009 restricted shares will vest in two installments as follows: 8,505 shares on December 21, 2019 and 8,504 shares on December 21, 2020.
- F4Of the 2,783,188 shares, 1,071,784 shares are restricted stock.